



## Attorney Docket P0998D1 **PATENT**

CERTIFICATION UNDER 37 CFR 1.10

EM 168 882 244 US: Express Mail Number

March 18, 1999: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein care being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**BOX PATENT APPLICATION** Assistant Commissioner of Patents Washington, D.C. 20231

# NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:


Inventor(s) (or Application "Identifier"):

Jeffrey L. Cleland Xanthe M. Lam Janet Yu-Feng Yang David E. Overcashier Chung C. Hsu

Title:

PROTEIN FORMULATION

- 1. Type of Application
- This application is for an original, non-provisional application. ()
- () This is a non-provisional application claiming priority to provisional application no. \_, filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.
- (x) This is a () continuation-in-part () continuation (x) divisional application claiming priority to application Serial Number 08/615,369, filed March 14, 1996 , the entire disclosure of which is hereby incorporated by reference.
- 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)
  - 43 pages of specification
  - \_ pages of claims
  - page(s) of abstract
  - sheet(s) of drawings () formal (x) informal



3.	Declaration or Oath					
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added.  An executed declaration of the inventor(s) () is enclosed () will follow.					
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted)  x A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).					
	(for Cont./Div. where inventor(s) being deleted)  _x A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).					
4.	Assignment					
	(for new and CIP applications)  An Assignment of the invention to GENENTECH, INC. () is enclosed with attached Recordation Form Cover Sheet () will follow.					
	(for cont./div.)x_ The prior application is assigned of record to Genentech, Inc.					
5.	Amendments (for continuation and divisional applications)					
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)					
	x A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)					
	Relate Back 35 U.S.C. 120 or 35 U.S.C. 119					
	Amend the specification by inserting before the first line the sentence:					
	This is a					
	non-provisional application continuation divisional					
	continuation-in-part of co-pending application(s)					
	Social No. filed on which application(s) is are incorporated berein by reference					

P0998D1 Page 3 of 4

and to which application(s) priority is claimed under 35 USC §120					
International Application filed on which designated the U.S., which					
application(s) is(are) incorporated herein by reference and to which application(s)					
priority is claimed under 35 USC §120					
 provisional application No filed, the entire disclosure of which is hereby					
incorporated by reference and to which application(s) priority is claimed under 35					
USC §119					

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

	<del></del>	Tediedidied e						
CLAIMS FOR FEE CALCULATION								
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)			
					\$760.00			
Total Claims	14	- 20 =	0	X \$18.00	\$0.00			
Independen † Claims	4	- 3=	1	X \$78.00	\$78.00			
_	\$0.00							
	\$838.00							

## 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$838.00. A duplicate copy of this transmittal is enclosed.

### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed</u>.

### 9. Additional Papers Enclosed

- (x) Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449.
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- () A new Power of Attorney or authorization of agent.
- () Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

(This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run)

A petition, fee and/or response has been filed to extend the term in the pending prior application until

A copy of the petition for extension of time in the *prior* application is

attached.

- 11. Correspondence Address:
- X Address all future communications to:

GENENTECH, INC. Attn: Wendy M. Lee 1 DNA Way South San Francisco, CA 94080-4990 (650) 225-1994

Respectfully submitted, GENENTECH, INC.

Date: March 18, 1999

Wendy M. Lee Reg. No. 40,378

1 DNA Way So. San Francisco, CA 94080-4990 Phone: (650) 225-1994

Fax: (650) 952-9881